- Home
- QFIN vs LNTH Comparison
QFIN vs LNTH Comparison
Compare QFIN & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QFIN
- LNTH
- Stock Information
- Founded
- QFIN 2016
- LNTH 1956
- Country
- QFIN China
- LNTH United States
- Employees
- QFIN N/A
- LNTH N/A
- Industry
- QFIN Finance: Consumer Services
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- QFIN Finance
- LNTH Health Care
- Exchange
- QFIN Nasdaq
- LNTH Nasdaq
- Market Cap
- QFIN 3.4B
- LNTH 3.8B
- IPO Year
- QFIN 2018
- LNTH 2015
- Fundamental
- Price
- QFIN $23.66
- LNTH $56.05
- Analyst Decision
- QFIN Strong Buy
- LNTH Buy
- Analyst Count
- QFIN 2
- LNTH 6
- Target Price
- QFIN $45.10
- LNTH $74.50
- AVG Volume (30 Days)
- QFIN 2.0M
- LNTH 1.4M
- Earning Date
- QFIN 11-18-2025
- LNTH 11-06-2025
- Dividend Yield
- QFIN 7.14%
- LNTH N/A
- EPS Growth
- QFIN 68.82
- LNTH N/A
- EPS
- QFIN 7.06
- LNTH 3.77
- Revenue
- QFIN $2,618,582,596.00
- LNTH $1,520,653,000.00
- Revenue This Year
- QFIN $17.10
- LNTH N/A
- Revenue Next Year
- QFIN $6.28
- LNTH $2.25
- P/E Ratio
- QFIN $3.01
- LNTH $14.71
- Revenue Growth
- QFIN 9.77
- LNTH 5.75
- 52 Week Low
- QFIN $20.45
- LNTH $47.25
- 52 Week High
- QFIN $48.94
- LNTH $118.21
- Technical
- Relative Strength Index (RSI)
- QFIN 39.43
- LNTH 52.22
- Support Level
- QFIN $20.67
- LNTH $56.03
- Resistance Level
- QFIN $27.59
- LNTH $58.30
- Average True Range (ATR)
- QFIN 1.24
- LNTH 1.60
- MACD
- QFIN -0.31
- LNTH 0.07
- Stochastic Oscillator
- QFIN 44.92
- LNTH 48.09
About QFIN Qifu Technology Inc.
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.